Breaking News Instant updates and real-time market news.

REGN

Regeneron

$377.80

-6.4 (-1.67%)

, SNY

Sanofi

$43.45

0.56 (1.31%)

05:30
10/16/18
10/16
05:30
10/16/18
05:30

Regeneron, Sanofi announce Phse 3 Dupixent trials met all endpoints

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that both pivotal Phase 3 placebo-controlled trials evaluating Dupixent in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps, met all their primary and secondary endpoints. On the co-primary endpoints for both trials at 24 weeks, patients treated with Dupixent added to a standard-of-care corticosteroid nasal spray experienced a 51% and 57% improvement in their nasal congestion/obstruction severity compared to a 15% and 19% improvement with nasal spray alone. Dupixent-treated patients had a 27% and 33% reduction in their nasal polyps score compared to a 4% and 7% increase for placebo. Dupixent also met all secondary endpoints in both trials, including demonstrating a significant reduction in the need for systemic corticosteroids or surgery, and improvements in smell and chronic rhinosinusitis symptoms. In a pre-specified group of patients with comorbid asthma, Dupixent significantly improved lung function and asthma control. Dupixent blocks the IL-4 and IL-13 signaling pathways.

REGN

Regeneron

$377.80

-6.4 (-1.67%)

SNY

Sanofi

$43.45

0.56 (1.31%)

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

REGN Regeneron
$377.80

-6.4 (-1.67%)

10/11/18
PIPR
10/11/18
NO CHANGE
Target $450
PIPR
Overweight
Piper remains buyer of Regeneron ahead of October 20 FDA action date
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Regeneron Pharmaceuticals (REGN) ahead of the Dupixent asthma October 20 FDA action date. With consensus expecting this indication to contribute well over $1B in revenue in coming years, approval is a "critical near-term catalyst" for the shares, Raymond tells investors in a research note. The analyst adds that while some investors have expressed angst over the breadth of the label, namely restricting use to eosinophilic asthma, he believes recent Sanofi (SNY) commentary provides reason for optimism. The totality of clinical data and the biology behind Dupixent supports a broad label, Raymond contends. He maintains an Overweight rating on Regeneron with a $450 price target.
10/01/18
LEER
10/01/18
NO CHANGE
Target $512
LEER
Outperform
Regeneron price target raised to $512 from $506 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Regeneron to $512 from $506 after the FDA approved the jointly developed and commercialized REGN/SNY PD-1 antibody cemiplimab, now known as Libtayo. The analyst reiterates an Outperform rating on the shares.
10/01/18
CANT
10/01/18
INITIATION
Target $415
CANT
Neutral
Regeneron initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Regeneron Pharmaceuticals with a Neutral rating and $415 price target.
10/01/18
PIPR
10/01/18
NO CHANGE
PIPR
Overweight
Piper keeps Overweight on Regeneron after Libtayo approval
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) after Friday's FDA approval of Libtayo in cutaneous squamous cell carcinoma. Timing is about a month ahead of the late-October FDA action date for Regeneron/Sanofi's (SNY) PD-1 inhibitor, but a positive decision was expected given the drug's "compelling data" in advanced CSCC, Raymond tells investors in a research note. While Libtayo will enter the market as the sixth approved PD-(L)1 inhibitor and third approved PD-1 agent, Raymond thinks readouts from the ongoing development program in other indications such as first-line non-small-cell lung carcinoma may make the case for moderate Libtayo uptake. However, he continues to like the set-up for Regeneron shares going forward.
SNY Sanofi
$43.45

0.56 (1.31%)

10/09/18
BARD
10/09/18
INITIATION
Target $50
BARD
Outperform
Principia Biopharma initiated with an Outperform at Baird
Baird analyst Brian Skorney started Principia Biopharma (PRNB) with an Outperform rating and $50 price target, stating that its BTK inhibitor partnered with Sanofi (SNY) for multiple sclerosis has blockbuster potential. He also believes PRN1008, which is entering Phase 3, has a worldwide opportunity over $500M in pemphigus that would also open the door for a host of other indications.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
Sanofi initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Sanofi with a Neutral rating and EUR83 price target. He sees its low earnings risk, strong dividend, and reasonable valuation being offset by competitive intensity building for Dupixent and its hemophilia franchises.

TODAY'S FREE FLY STORIES

USD

VeriSign Inc

$50.70

(0.00%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
VeriSign Inc falls -6.9% »

VeriSign Inc is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTV

Fortive

$80.98

-6.78 (-7.73%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
Fortive falls -7.8% »

Fortive is down -7.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATEN

A10 Networks

$6.31

-0.97 (-13.32%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
A10 Networks falls -13.6% »

A10 Networks is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRO

Pros Holdings

$45.06

(0.00%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
Pros Holdings rises 9.3% »

Pros Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

ENVA

Enova International

$30.38

3.85 (14.51%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
Enova International rises 14.4% »

Enova International is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 09

    May

  • 30

    May

  • 13

    Nov

GRUB

GrubHub

$76.84

7.01 (10.04%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
GrubHub rises 10.3% »

GrubHub is up 10.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 28

    May

  • 05

    Jun

SPY

SPDR S&P 500 ETF Trust

$292.02

-0.1 (-0.03%)

, SPX

S&P 500

$0.00

(0.00%)

09:46
04/26/19
04/26
09:46
04/26/19
09:46
Hot Stocks
Kudlow says trade deal with China 'is not done' »

Larry Kudlow, director of…

SPY

SPDR S&P 500 ETF Trust

$292.02

-0.1 (-0.03%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
04/26/19
04/26
09:45
04/26/19
09:45
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

SBUX

Starbucks

$77.07

(0.00%)

09:41
04/26/19
04/26
09:41
04/26/19
09:41
Recommendations
Starbucks analyst commentary  »

Starbucks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

09:40
04/26/19
04/26
09:40
04/26/19
09:40
On The Fly
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

SSNLF

Samsung

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

JPM

JPMorgan

$113.62

(0.00%)

AMD

AMD

$27.66

(0.00%)

NVDA

Nvidia

$186.84

(0.00%)

OSTK

Overstock.com

$13.13

(0.00%)

DPW

DPW Holdings

$0.22

(0.00%)

KODK

Kodak

$2.38

(0.00%)

IDEX

Ideanomics

$1.84

(0.00%)

RIOT

Riot Blockchain

$5.90

(0.00%)

TEUM

Pareteum

$3.90

(0.00%)

SRAX

Social Reality

$4.80

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 30

    Apr

  • 07

    May

  • 09

    May

  • 14

    May

  • 15

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 10

    Jun

  • 11

    Jun

  • 24

    Jun

  • 25

    Jun

  • 16

    Jul

F

Ford

$9.41

(0.00%)

, JNPR

Juniper

$28.12

(0.00%)

09:40
04/26/19
04/26
09:40
04/26/19
09:40
Options
Unusually active option classes on open April 26th »

Unusual total active…

F

Ford

$9.41

(0.00%)

JNPR

Juniper

$28.12

(0.00%)

WMT

Walmart

$103.52

(0.00%)

INTC

Intel

$57.59

(0.00%)

GRUB

GrubHub

$69.83

(0.00%)

AMZN

Amazon.com

$1,902.53

(0.00%)

MRVL

Marvell

$25.42

(0.00%)

XOM

Exxon Mobil

$82.25

(0.00%)

KR

Kroger

$25.77

(0.00%)

WDC

Western Digital

$52.95

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 29

    Apr

  • 01

    May

  • 03

    May

  • 06

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 14

    May

  • 16

    May

  • 16

    May

  • 21

    May

  • 22

    May

  • 28

    May

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 24

    Jul

  • 25

    Jul

  • 23

    Oct

  • 13

    Nov

09:40
04/26/19
04/26
09:40
04/26/19
09:40
General news
Fed Policy Outlook: analysts continue to take issue with the market's dovish bet »

Fed Policy Outlook:…

AAPL

Apple

$205.28

-1.82 (-0.88%)

09:39
04/26/19
04/26
09:39
04/26/19
09:39
Recommendations
Apple analyst commentary at OTR Global »

Apple incentives not much…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    Jun

HIBB

Hibbett Sports

$20.53

0.13 (0.64%)

, TSCO

Tractor Supply

$105.09

1 (0.96%)

09:37
04/26/19
04/26
09:37
04/26/19
09:37
Hot Stocks
Hibbett Sports names Christine Skold as Interim CFO, effective April 26 »

Hibbett Sports (HIBB)…

HIBB

Hibbett Sports

$20.53

0.13 (0.64%)

TSCO

Tractor Supply

$105.09

1 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

  • 23

    May

  • 25

    Jul

  • 13

    Nov

SBUX

Starbucks

$77.07

0.65 (0.85%)

09:37
04/26/19
04/26
09:37
04/26/19
09:37
Hot Stocks
Starbucks CEO says competitor discounts in China not sustainable »

Kevin Johnson is speaking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$161.03

-0.47 (-0.29%)

09:36
04/26/19
04/26
09:36
04/26/19
09:36
Recommendations
Visa analyst commentary at BMO Capital »

Visa price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

  • 29

    May

  • 05

    Jun

WNS

WNS Holdings

$56.71

0.26 (0.46%)

09:36
04/26/19
04/26
09:36
04/26/19
09:36
Recommendations
WNS Holdings analyst commentary at Barrington »

WNS Holdings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ANTM

Anthem

$256.01

5 (1.99%)

, CVS

CVS Health

$53.24

0.31 (0.59%)

09:34
04/26/19
04/26
09:34
04/26/19
09:34
Recommendations
Anthem, CVS Health analyst commentary at Cleveland Research »

Anthem won Blue Cross of…

ANTM

Anthem

$256.01

5 (1.99%)

CVS

CVS Health

$53.24

0.31 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 07

    May

  • 15

    May

  • 16

    May

  • 19

    May

  • 29

    May

  • 18

    Jun

RL

Ralph Lauren

$129.74

-2.31 (-1.75%)

09:34
04/26/19
04/26
09:34
04/26/19
09:34
Upgrade
Ralph Lauren rating change  »

Ralph Lauren upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SFLY

Shutterfly

$42.30

-0.65 (-1.51%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Upgrade
Shutterfly rating change at Raymond James »

Shutterfly upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

HTBK

Heritage Commerce

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Downgrade
Heritage Commerce rating change at Brean Capital »

Heritage Commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

SIVB

SVB Financial

$247.10

-1.84 (-0.74%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Downgrade
SVB Financial rating change at Fig Partners »

SVB Financial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 08

    May

  • 09

    May

MAS

Masco

$37.50

-2.48 (-6.20%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Upgrade
Masco rating change at Raymond James »

Masco upgraded two levels…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

FLGT

Fulgent Genetics

$7.23

-0.02 (-0.28%)

09:31
04/26/19
04/26
09:31
04/26/19
09:31
Downgrade
Fulgent Genetics rating change at Credit Suisse »

Fulgent Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

09:30
04/26/19
04/26
09:30
04/26/19
09:30
Recommendations
Pros Holdings analyst commentary at DA Davidson »

ProsHoldings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.